2022
Cytomegalovirus-related Complications and Management in Facial Vascularized Composite Allotransplantation: An International Multicenter Retrospective Cohort Study
Kauke-Navarro M, Panayi AC, Formica R, Marty F, Parikh N, Foroutanjazi S, Safi AF, Mardini S, Razonable RR, Morelon E, Gelb B, Rodriguez E, Lassus P, Pomahac B. Cytomegalovirus-related Complications and Management in Facial Vascularized Composite Allotransplantation: An International Multicenter Retrospective Cohort Study. Transplantation 2022, 106: 2031-2043. PMID: 35389381, DOI: 10.1097/tp.0000000000004132.Peer-Reviewed Original ResearchConceptsRetrospective cohort studyAntiviral prophylaxisCohort studyComposite allotransplantationInternational multicenter retrospective cohort studyMulticenter retrospective cohort studyCMV-related complicationsFirst year posttransplantHigh-risk transplantsMore rejection episodesHigh-risk groupFacial Vascularized Composite AllotransplantationAllograft-related complicationsVascularized Composite AllotransplantationPaucity of dataAllograft lossCMV diseaseCMV viremiaCytomegalovirus serostatusR serostatusRejection episodesCMV infectionPrompt treatmentActive surveillancePatients
2019
Association between lymphocyte subsets and cytomegalovirus infection status among patients with systemic lupus erythematosus
Qin L, Qiu Z, Hsieh E, Geng T, Zhao J, Zeng X, Wan L, Xie J, Ramendra R, Routy JP, Li T. Association between lymphocyte subsets and cytomegalovirus infection status among patients with systemic lupus erythematosus. Medicine 2019, 98: e16997. PMID: 31574798, PMCID: PMC6775378, DOI: 10.1097/md.0000000000016997.Peer-Reviewed Original ResearchConceptsSystemic lupus erythematosusCMV diseaseLymphocyte subsetsCMV viremiaT cellsSLE patientsCMV infectionInfection statusLupus erythematosusNatural killer cell countsMultivariable logistic regression analysisCMV infection statusCytomegalovirus infection statusEvidence of CMVHospitalized SLE patientsLymphocyte subset countsDifferent lymphocyte subsetsCMV-infected patientsT-cell lymphopeniaLogistic regression analysisTotal lymphocytesUninfected patientsClinical characteristicsSubset countsMultivariable analysis
2017
Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial of RG7667, a Combination Monoclonal Antibody, for Prevention of Cytomegalovirus Infection in High-Risk Kidney Transplant Recipients
Ishida JH, Patel A, Mehta AK, Gatault P, McBride JM, Burgess T, Derby MA, Snydman DR, Emu B, Feierbach B, Fouts AE, Maia M, Deng R, Rosenberger CM, Gennaro LA, Striano NS, Liao XC, Tavel JA. Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial of RG7667, a Combination Monoclonal Antibody, for Prevention of Cytomegalovirus Infection in High-Risk Kidney Transplant Recipients. Antimicrobial Agents And Chemotherapy 2017, 61: 10.1128/aac.01794-16. PMID: 27872061, PMCID: PMC5278717, DOI: 10.1128/aac.01794-16.Peer-Reviewed Original ResearchConceptsHigh-risk kidney transplant recipientsKidney transplant recipientsCMV viremiaTransplant recipientsCMV diseaseCMV infectionCytomegalovirus infectionMonoclonal antibodiesCMV-seronegative recipientsCMV-seropositive donorsLess CMV diseasePlacebo-controlled trialTime of transplantKidney transplantationPlacebo groupAdverse eventsKidney transplantMedian timeSignificant complicationsPlaceboTreatment groupsPatientsViremiaInfectionWeeks
2012
Infections Following Facial Composite Tissue Allotransplantation—Single Center Experience and Review of the Literature
Knoll B, Hammond S, Koo S, Issa N, Tullius S, Baden L, Pomahac B, Marty F. Infections Following Facial Composite Tissue Allotransplantation—Single Center Experience and Review of the Literature. American Journal Of Transplantation 2012, 13: 770-779. PMID: 23279299, DOI: 10.1111/ajt.12013.Peer-Reviewed Original ResearchMeSH KeywordsAdultAnti-Infective AgentsCatheter-Related InfectionsCytomegalovirusCytomegalovirus InfectionsFaceFemaleGraft RejectionGraft SurvivalHumansMaleMiddle AgedPneumoniaPostoperative ComplicationsPrognosisSurgical Wound InfectionTissue TransplantationTransplantation, HomologousTrimethoprim, Sulfamethoxazole Drug CombinationConceptsFacial composite tissue allotransplantationCMV diseaseInfectious complicationsPosttransplant infectionsClostridium difficile-associated diarrheaDiscontinuation of prophylaxisEarly posttransplant infectionsSurgical site infectionDifficile-associated diarrheaCatheter-associated infectionsComposite tissue allotransplantationInvasive dermatophyte infectionAdditional prophylaxisBacterial parotitisPerioperative prophylaxisValganciclovir treatmentCenter experienceProphylaxis strategiesSite infectionPolymicrobial bacteremiaRecipient factorsTrimethoprim-sulfamethoxazoleMedical recordsDermatophyte infectionsProphylaxis
1998
Lack of reactivity to CMV pp65 antigenemia testing in a patient with CMV disease following allogeneic bone marrow transplant
Seropian S, Ferguson D, Salloum E, Cooper D, Landry M. Lack of reactivity to CMV pp65 antigenemia testing in a patient with CMV disease following allogeneic bone marrow transplant. Bone Marrow Transplantation 1998, 22: 507-509. PMID: 9733277, DOI: 10.1038/sj.bmt.1701354.Peer-Reviewed Original ResearchConceptsPeripheral blood leukocytesAntigenemia testingCMV diseaseCMV infectionAntiviral therapyBlood leukocytesPre-emptive antiviral therapyAllogeneic bone marrow transplantationAllogeneic bone marrow transplantAntibody poolEarly detectionCMV pp65 antigenemiaBone marrow transplantationBone marrow transplantPeripheral blood specimensPeripheral blood samplesAllogeneic BMTLiver transaminasesPp65 antigenemiaAbnormal transaminasesMarrow transplantationMarrow transplantViral cultureAplastic anemiaBronchial lavage
1996
Use of a quantitative cytomegalovirus (CMV) antigenemia test in evaluating HIV+ patients with and without CMV disease.
Wetherill PE, Landry ML, Alcabes P, Friedland G. Use of a quantitative cytomegalovirus (CMV) antigenemia test in evaluating HIV+ patients with and without CMV disease. JAIDS Journal Of Acquired Immune Deficiency Syndromes 1996, 12: 33-7. PMID: 8624758, DOI: 10.1097/00042560-199605010-00005.Peer-Reviewed Original ResearchMeSH KeywordsAdultAIDS-Related Opportunistic InfectionsAntibodies, MonoclonalAntigens, ViralCross-Sectional StudiesCytomegalovirusCytomegalovirus InfectionsCytomegalovirus RetinitisFemaleFluorescent Antibody TechniqueHIV SeropositivityHIV-1HumansLeukocytesMaleMiddle AgedPredictive Value of TestsRetrospective StudiesViral Matrix ProteinsViremiaConceptsCMV antigenemia testCMV diseaseAntigenemia testCMV antigenemiaHIV diseaseCytomegalovirus antigenemia testPositive CMV antigenemiaLife-threatening infectionsDiagnostic techniquesAntigenemia levelsAntigenemia resultsCMV retinitisCytomegalovirus infectionCMV cultureClinical evidenceOphthalmologic examPatientsDiseaseRapid diagnosisAntigenemiaInfectionDiagnosisQuantitative diagnostic techniqueRetinitisHIV
1985
EFFECT OF TREATMENT WITH CYCLOSPORINE VERSUS AZATHIOPRINE ON INCIDENCE AND SEVERITY OF CYTOMEGALOVIRUS INFECTION POSTTRANSPLANTATION
Bia M, Andiman W, Gaudio K, Kliger A, Siegel N, Smith D, Flye W. EFFECT OF TREATMENT WITH CYCLOSPORINE VERSUS AZATHIOPRINE ON INCIDENCE AND SEVERITY OF CYTOMEGALOVIRUS INFECTION POSTTRANSPLANTATION. Transplantation 1985, 40: 610-614. PMID: 3000031, DOI: 10.1097/00007890-198512000-00007.Peer-Reviewed Original ResearchConceptsAntithymocyte globulinSteroid-resistant rejectionRenal transplant patientsCMV infectionAzathioprine groupCMV diseaseTransplant patientsEffect of ATGUse of ATGAzathioprine-treated patientsCMV antibody titersCyclosporine-treated patientsNumber of patientsCulture of urineEffect of treatmentATG therapyCadaveric recipientsInfection posttransplantationAdditional therapyCytomegalovirus infectionDrug regimensImmunosuppressive drugsAntibody titersAzathioprinePatients
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply